U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07810933) titled 'A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies' on Sept. 02.
Brief Summary: A phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of SY-12321 in trial participants with ALK-positive advanced malignancies, including non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor (IMT), anaplastic large-cell lymphoma (ALCL), colorectal cancer, pancreatic cancer, breast cancer, and others.
Study Start Date: Aug. 12
Study Type: INTERVENTIONAL
Condition:
ALK Positive Advanced Malignancies
Intervention:
DRUG: SY-12321
A fourth-g...